Transperineal ultrasound guided I-125/Pd-103 brachytherapy for early stage prostate cancer: Update on clinical experience at seven years

被引：4
|
作者：
Grimm, PD
Blasko, J
Ragde, H
Sylvester, J
Cavanagh, W
机构：
[1] SWEDISH MED CTR,NW PROSTATE INST,SEATTLE,WA
[2] UNIV WASHINGTON,MED CTR,DEPT RADIAT ONCOL,SEATTLE,WA 98195
[3] NORTHWEST HOSP,SEATTLE,WA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1997年 / 39卷 / 02期
关键词：
D O I：
10.1016/S0360-3016(97)80726-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：219 / 219
页数：1
相关论文
共 50 条
  • [21] Interstitial brachytherapy of the prostate with Pd-103 and iodine-125, toxicity comparison and results after 6.5 years
    Oismueller, R.
    Somay, C.
    Buehler, F.
    Ponholzer, A.
    Hawliczek, R.
    Maderbacher, St.
    Rauchenwald, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 194 - 194
  • [22] Producing a Look-Up Table for Mesh Brachytherapy Dosimetry with I-125, Pd-103, and Cs-131
    Grelewicz, Z.
    Cutright, D.
    Sathiaseelan, V.
    Zhang, H.
    MEDICAL PHYSICS, 2017, 44 (06)
  • [23] Edema associated with I-125 or Pd-103 prostate brachytherapy and its effect on post-implant dosimetry: An analysis based on serial CT acquisition
    Waterman, FM
    Yue, N
    Corn, BW
    Dicker, AP
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 220 - 220
  • [24] Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition
    Waterman, FM
    Yue, N
    Corn, BW
    Dicker, AP
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (05): : 1069 - 1077
  • [25] I-125 versus Pd-103 for low-risk prostate cancer: Morbidity outcomes from a prospective randomized multicenter trial
    Wallner, K
    Merrick, G
    True, L
    Cavanagh, W
    Simpson, C
    Butler, W
    CANCER JOURNAL, 2002, 8 (01): : 67 - 73
  • [26] Shortcomings in published brachytherapy source parameters for accurate dose calculation for an eye plaque implant with I-125 or Pd-103 seeds
    Awan, S.
    Meigooni, A.
    Dini, S.
    Chen, Y.
    Khan, F.
    Cole, J.
    MEDICAL PHYSICS, 2007, 34 (06) : 2488 - 2489
  • [27] Microdosimetric evaluation of relative biological effectiveness for Pd-103, I-125, (241)AM, and Ir-192 brachytherapy sources
    Wuu, CS
    Kliauga, P
    Zaider, M
    Amols, HI
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (03): : 689 - 697
  • [28] New methods for anisotropy characterization of Pd-103 and I-125 prostate brachytherapy seed emissions using radiochromic film and angular x-ray spectrometry
    Mitch, M
    Lamperti, P
    Seltzer, S
    Coursey, B
    MEDICAL PHYSICS, 2002, 29 (06) : 1228 - 1228
  • [29] Transperineal I-125 implants for early prostate cancer: Rambam Medical Center, Israel
    Gez, E
    Genesin, J
    Shahar, D
    Bar-Deroma, R
    Machtey, A
    Yereslav, N
    Meretick, S
    Kuten, A
    RADIOTHERAPY AND ONCOLOGY, 2005, 75 : S35 - S36
  • [30] Fractional integral target dose comparison for I-125, Pd-103 and Cs-131 in prostate seed implants
    Li, T.
    Fountain, L.
    Duff, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S566 - S567
12345